Opinion|Videos|July 30, 2024
Emerging Data with BTKi Resistance: Expert Insights and Treatment Implications
The panel addresses the intricacies of treating patients with chronic lymphocytic leukemia who experience treatment resistance.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- Briefly discuss insights regarding emerging resistance data and its potential implications on treatment decisions/practices.
- In patients who progress on 1L therapy with BTKi, do you test for the presence of BTK resistance mutations?
- How do you interpret available data to the clinical practice setting?
Advertisement
Related to this article
Pooled results from the phase 3 BRUIN CLL-313 and BRUIN CLL-314 trials confirmed the efficacy of pirtobrutinib in treatment-naive CLL.
A post hoc analysis found similar safety outcomes for fixed-duration regimens containing acalabrutinib/venetoclax across age groups in treatment-naive CLL.
In an OncLive Peer Exchange, experts discussed the evolving treatment landscape in CLL, spanning frontline selection to emerging next-generation agents.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
Advertisement
Advertisement
Trending on OncLive
1
ASCO Issues First Guideline on ctDNA Testing in Solid Tumors and Lymphoma
2
Darlifarnib Plus Cabozantinib Displays Early Signals of Safety and Efficacy in RCC
3
Five Under 5: Top Oncology Videos for the Week of 8/16
4
The OncFive: Top Oncology Articles for the Week of 8/16
5